Mode
Text Size
Log in / Sign up
N/A N=23 Treatment

Feasibility Study of the TruSculpt Radiofrequency Device

Tissue Tightening

Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcome: Primary: Investigator Assessment of Improvement — 0.67 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
TruSculpt (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cutera Inc.
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Investigator Assessment of Improvement
0.67

Summary

A single-center, prospective, open-label feasibility study of the truSculpt radiofrequency device.

Eligibility Criteria

Inclusion Criteria

  • Male or Female, 18 to 70 years of age (inclusive)
  • Fitzpatrick Skin Type I - VI
  • Has visible fat bulges, skin laxity, or cellulite in the treatment area
  • Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study.
  • Subject must agree to not undergo any other procedure(s) in the treatment area during the study period.
  • Subject must be able to read, understand and sign the Informed Consent Form.
  • Subject must adhere to the follow-up schedule and study instructions.
  • Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
  • Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant.

Exclusion Criteria

  • Participation in a clinical trial of another device or drug in the target area during the study period.
  • Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant.
  • Has metal implant(s) within the body that is local to the treatment area, such as surgical clips, plates and screws, intrauterine device (IUD), artificial heart valves or artificial joints.
  • Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, peripheral vascular disease or pertinent neurological disorders.
  • Diagnosed or documented immune system disorders.
  • History of any disease or condition that could impair wound healing.
  • History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
  • Infection, dermatitis, rash or other skin abnormality in the target area.
  • Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation.
  • Pregnant or currently breastfeeding.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03018587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search